Projected Target Price for VTWG Analyst: $286

Written by Emily J. Thompson, Senior Investment Analyst

EWTX+1.85%

VTWG+0.9%

SMLR-5.12%

Source: NASDAQ.COM

Updated: Oct 09 2025

0mins

Source: NASDAQ.COM

Vanguard Russell 2000 Growth ETF Analysis: The Vanguard Russell 2000 Growth ETF (VTWG) has an implied analyst target price of $286.24, indicating a potential upside of 19.42% from its current trading price of $239.69.
Notable Holdings with Upside Potential: Key underlying holdings such as Janux Therapeutics (JANX), Semler Scientific (SMLR), and Edgewise Therapeutics (EWTX) show significant upside potential, with target prices suggesting increases of 223.86%, 167.14%, and 145.55%, respectively, compared to their recent trading prices.

EWTX

$29.78+Infinity%1D

Analyst Views on EWTX

Wall Street analysts forecast EWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EWTX is 38.14 USD with a low forecast of 16.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Analyst Rating

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 29.240

Low

16.00

Averages

38.14

High

51.00

Current: 29.240

Low

16.00

Averages

38.14

High

51.00

JPMorgan

Overweight

maintain

2025-12-26

Reason

JPMorgan

Price Target

AI Analysis

2025-12-26

maintain

Overweight

Reason

JPMorgan was "encouraged" by the latest updates from Edgewise Therapeutics' ongoing phase 2 CIRRUS-HCM trial for EDG-7500 in obstructive HCM and nonobstructive HCM, which the firm sees reinforcing the "overall intriguing product profile" as a potential future treatment option for patients. The firm, which views EDG-7500 as on the "right track," thinks the full 12 week data from Part D due in Q2 of 2026 will be "more meaningful" in terms of EDG-7500's potential, as well as provide more information around dose optimization in both the oHCM and nHCM patient populations, the analyst tells investors. JPMorgan has an Overweight rating on Edgewise shares.

Truist

Buy

maintain

$46

2025-12-24

Reason

Truist

Price Target

$46

2025-12-24

maintain

Buy

Reason

Truist keeps a Buy rating and $46 price target on Edgewise Therapeutics following the company's updates from Phase 2 EDG-7500 trial in Hypertrophic Cardiomyopathy, or HCM. Edgewise reported data from both 25mg dose as well as interim data from part D of the study, and the firm remains bullish of the opportunity for EDG-7500 in both obstructive HCM and non-obstructive HCM given signs of efficacy in both patient groups, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EWTX

Unlock Now

Stifel

Hold

maintain

2025-12-24

Reason

Stifel

Price Target

2025-12-24

maintain

Hold

Reason

Stifel notes that Hold-rated Edgewise Therapeutics reported an EDG-7500 update, with Parts B & C 25mg efficacy/safety data and an interim Part D safety update, which include one additional case of new-onset atrial fibrillation. The firm thinks the update still leaves questions on safety that'll take more than additional open-label data to disprove. And for the stock, the broader challenge is that there might be no afib signal, but '7500 now has a titration which was an original/core differentiator; or there is an actual afib signal. Stifel doesn't think and answer will be known until longer-term/controlled Phase 3 data, which are years away. In the meantime, regulators -- and physicians -- are only getting more comfortable with the cardiac myosin inhibitor class; and the next big catalyst for the stock is Phase 3 bone mineral density data in Q4 2026, which the firm continues to struggle to build conviction in.

H.C. Wainwright

Buy

maintain

$42

2025-12-24

Reason

H.C. Wainwright

Price Target

$42

2025-12-24

maintain

Buy

Reason

H.C. Wainwright maintains a Buy rating and $42 price target on Edgewise Therapeutics after the company announced additional CIRRUS-HCM Part B and C results evaluating a lower 25 mg fixed-dose of EDG-7500 in oHCM and nHCM participantsResults from the 25 mg dose demonstrated sustained clinical activity across key HCM disease markers, while maintaining a favorable safety profile, says the analyst, who sees the data reinforcing EDG-7500's potential for differentiation.

About EWTX

Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.